By Artem Andrianov, Ph.D., MBA|2017-05-24T16:12:17+00:00May 24, 2017|Comments Off on FMEA graph clinical trial
About the Author: Artem Andrianov, Ph.D., MBA
Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.